144 related articles for article (PubMed ID: 28369138)
1. TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.
Xu P; Liu X; Ouyang J; Chen B
PLoS One; 2017; 12(4):e0174809. PubMed ID: 28369138
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
3. No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma.
Havranek O; Spacek M; Hubacek P; Mocikova H; Benesova K; Soucek P; Trneny M; Kleibl Z
Leuk Res; 2011 Aug; 35(8):1117-9. PubMed ID: 21546086
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.
Dong C; Yuan Z; Li Q; Wang Y
Neurol Sci; 2018 Jul; 39(7):1191-1201. PubMed ID: 29651718
[TBL] [Abstract][Full Text] [Related]
5. Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis.
Lizhi L; Rongdong H; Shaohua H; Yingquan K; Huihuang X; Shan L; Kunbin T; Di X
Fetal Pediatr Pathol; 2021 Dec; 40(6):653-662. PubMed ID: 32066305
[No Abstract] [Full Text] [Related]
6. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.
Zainuddin N; Berglund M; Wanders A; Ren ZP; Amini RM; Lindell M; Kanduri M; Roos G; Rosenquist R; Enblad G
Leuk Res; 2009 Jan; 33(1):60-6. PubMed ID: 18706692
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.
Fisher OM; Lord SJ; Falkenback D; Clemons NJ; Eslick GD; Lord RV
Gut; 2017 Mar; 66(3):399-410. PubMed ID: 26733670
[TBL] [Abstract][Full Text] [Related]
8. [p53 mutation does not determine prognosis in non-Hodgkin's lymphoma].
Osada M; Ishioka C; Murakawa Y; Ichinohasama R; Kanamaru R; Ikawa S
Gan To Kagaku Ryoho; 1997 Feb; 24(4):471-5. PubMed ID: 9063486
[TBL] [Abstract][Full Text] [Related]
9. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
[TBL] [Abstract][Full Text] [Related]
10. VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.
Yang J; Li W; He X; Zhang G; Yue L; Chai Y
Dis Markers; 2015; 2015():786790. PubMed ID: 25810565
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of latent membrane protein 1 expression in non-Hodgkin lymphoma: A meta-analysis.
Li XM; Xiao WH; Zhao HX
Medicine (Baltimore); 2017 Apr; 96(14):e6512. PubMed ID: 28383415
[TBL] [Abstract][Full Text] [Related]
12. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
13. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma.
Kim HN; Yu L; Kim NY; Lee IK; Kim YK; Yang DH; Lee JJ; Shin MH; Park KS; Choi JS; Kim HJ
Am J Hematol; 2010 Oct; 85(10):822-4. PubMed ID: 20734458
[TBL] [Abstract][Full Text] [Related]
14. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma.
Osada M; Ishioka C; Ichinohasama R; Kadowaki I; Murakawa Y; Watanabe M; Kanamaru R; Ikawa S
Anticancer Drug Des; 1999 Apr; 14(2):107-14. PubMed ID: 10405637
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T; Kreuz M; Fuge M; Klapper W; Horn H; Staiger AM; Winter D; Helfrich H; Huellein J; Hansmann ML; Stein H; Feller A; Möller P; Schmitz N; Trümper L; Loeffler M; Siebert R; Rosenwald A; Ott G; Pfreundschuh M; Stilgenbauer S;
Int J Cancer; 2017 Oct; 141(7):1381-1388. PubMed ID: 28614910
[TBL] [Abstract][Full Text] [Related]
17. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
19. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
